Net sales down 10.0% to €911.9 million, driven by lower volumes for Sanofi and the suspension of production at Brindisi, only ...

Operational resilience and strong increase in Free Cash Flow before financing in a challenging environment Net sales down 10.0% to €911.9 ...

Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial ...

Kuehne+Nagel supports Sanofi in multiple countries worldwide, including Hungary, the UK, and the UAE, by providing customised ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

NewAmsterdam Pharma's obicetrapib lowers LDL-C in Phase 3 trials, showing promise as a CETP inhibitor. Read more on NAMS ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or argenx SE is a better investment based on AAII's A+ Investor grades ...

Sanofi India share price gained up to 6% in morning trades on Friday post Q4 results announced by the company after the ...

With a market valuation of Rs 11,574.76 Cr, Sanofi Indias shares ended Fridays trading session on the BSE 0.58% higher at Rs ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The equity market witnessed a sharp decline today, with both benchmark indices dropping over 1%. By noon, the Sensex tumbled ...